1. Home
  2. CGEM vs PRAA Comparison

CGEM vs PRAA Comparison

Compare CGEM & PRAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGEM
  • PRAA
  • Stock Information
  • Founded
  • CGEM 2016
  • PRAA 1996
  • Country
  • CGEM United States
  • PRAA United States
  • Employees
  • CGEM N/A
  • PRAA N/A
  • Industry
  • CGEM Biotechnology: Pharmaceutical Preparations
  • PRAA Finance: Consumer Services
  • Sector
  • CGEM Health Care
  • PRAA Finance
  • Exchange
  • CGEM Nasdaq
  • PRAA Nasdaq
  • Market Cap
  • CGEM 730.2M
  • PRAA 834.7M
  • IPO Year
  • CGEM 2021
  • PRAA N/A
  • Fundamental
  • Price
  • CGEM $8.51
  • PRAA $21.66
  • Analyst Decision
  • CGEM Strong Buy
  • PRAA Strong Buy
  • Analyst Count
  • CGEM 7
  • PRAA 2
  • Target Price
  • CGEM $32.50
  • PRAA $32.00
  • AVG Volume (30 Days)
  • CGEM 420.6K
  • PRAA 226.8K
  • Earning Date
  • CGEM 03-13-2025
  • PRAA 02-19-2025
  • Dividend Yield
  • CGEM N/A
  • PRAA N/A
  • EPS Growth
  • CGEM N/A
  • PRAA N/A
  • EPS
  • CGEM N/A
  • PRAA 1.79
  • Revenue
  • CGEM N/A
  • PRAA $1,114,524,000.00
  • Revenue This Year
  • CGEM N/A
  • PRAA $7.04
  • Revenue Next Year
  • CGEM N/A
  • PRAA $7.29
  • P/E Ratio
  • CGEM N/A
  • PRAA $12.24
  • Revenue Growth
  • CGEM N/A
  • PRAA 38.87
  • 52 Week Low
  • CGEM $8.36
  • PRAA $18.64
  • 52 Week High
  • CGEM $30.19
  • PRAA $28.64
  • Technical
  • Relative Strength Index (RSI)
  • CGEM 27.85
  • PRAA 46.81
  • Support Level
  • CGEM $8.35
  • PRAA $21.79
  • Resistance Level
  • CGEM $9.51
  • PRAA $23.97
  • Average True Range (ATR)
  • CGEM 0.46
  • PRAA 0.74
  • MACD
  • CGEM -0.08
  • PRAA -0.20
  • Stochastic Oscillator
  • CGEM 11.91
  • PRAA 21.91

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.

About PRAA PRA Group Inc.

PRA Group Inc is a leader in acquiring and collecting nonperforming loans. The company returns capital to banks and other creditors to help expand financial services for consumers in the Americas, Europe, and Australia. It is also engaged in providing fee-based services on class action claims recoveries in the United States. The company's portfolio segments include; Core, which is engaged in purchasing and collecting nonperforming loans, which the originators have not chosen not to pursue, and the Insolvency segment which is engaged in purchasing and collecting nonperforming loans where the customer is involved in a bankruptcy proceeding.

Share on Social Networks: